November 20, 2007 -- China Aoxing Pharmaceutical Company (OTCBB: CAXG) received a license from the China State Food & Drug Administration to develop a maintenance treatment for opioid dependence. The treatment, a combination of buprenorphine and naloxone in a sublingual tablet, has been available in the US since 2002. It is marketed as Suboxone® by Schering-Plough (NYSE: SGP). China Aoxing has as its stated aim the low-risk strategy of bringing narcotic/pain drugs that are available in the west to China, so the announcement fits the business plan, though liquidity remains an issue. More details...
